Core Viewpoint - Chuangsheng Group-B (06628.HK) announced the grant of 2 million shares to one reward recipient under its share incentive plan on December 29, 2025 [1] Group 1 - The company is implementing a share incentive plan to motivate and reward employees [1] - The share grant consists of 2 million shares, which indicates a significant commitment to employee incentives [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Transcenta Holding Limited 創勝集團醫藥有限公司 （以存續方式於開曼群島註冊的有限公司） （股份代號：6628） 根據股份激勵計劃授出獎勵股份 根據上市規則第17.06A條，董事會宣佈，於2025年12月29日，本公司根據股份激 勵計劃向1名獎勵承授人授出2,000,000股獎勵股份（「12月獎勵授出」）。 12月獎勵授出的詳情載列如下： 授出獎勵股份的購買價： 零 股份於授出日期的 收市價： 每股股份2.17港元 授出獎勵股份的代價： 零 倘獎勵承授人因(i)獎勵承授人身故，(ii)永久性身體或 精神殘疾導致獎勵承授人與本集團或聯屬公司的僱傭 或合約聘用終止，(iii)裁員導致獎勵承授人與本集團的 僱傭或合約聘用終止，而不再為合資格人士，除非計 劃管理人全權酌情另行決定，否則任何未歸屬的已發 行在外獎勵股份及相關收入將即時沒收。 倘獎勵承授人為僱員，其因僱主在並無發出通知或支 ...

Core Insights - The company has entered into a strategic partnership and non-exclusive technology licensing agreement with EirGenix, a global biopharmaceutical development and manufacturing enterprise [1] - The agreement allows EirGenix to utilize the company's HiCB platform, which focuses on high-yield continuous flow upstream processes and integrated continuous downstream purification techniques [1] - The collaboration aims to enhance process efficiency, optimize process control, and ensure product consistency, significantly reducing production costs compared to traditional fed-batch production methods [1] Financial Aspects - The company will receive a substantial upfront payment and milestone payments, along with future royalties from the commercialization of the licensed technology [1] - The partnership is expected to create long-term value for both parties, reflecting a shared vision for the collaboration [1] Industry Impact - The HiCB platform is designed to improve the affordability and accessibility of biopharmaceuticals for patients globally [1] - EirGenix plans to use the HiCB platform to support its biopharmaceutical development projects and production operations, targeting CDMO clients seeking integrated continuous flow production solutions [1] Future Developments - The CEO of the company expressed optimism about sharing the HiCB platform with like-minded partners to drive innovation in biopharmaceutical production [2] - Future revenues generated from this and subsequent collaborations will be reinvested into strengthening the technology platform and advancing the research and development pipeline for next-generation therapies [2]

Core Viewpoint - The company has entered into a strategic partnership and non-exclusive technology licensing agreement with EirGenix, a global biopharmaceutical development and manufacturing firm, to leverage its HiCB platform for bioprocessing [1] Group 1: Partnership Details - The agreement grants EirGenix a non-exclusive license for the highly integrated continuous flow bioprocessing manufacturing (HiCB) platform, which includes high-yield continuous perfusion upstream processes and integrated mixed continuous downstream purification technology [1] - The company will provide comprehensive process documentation, core process technology, experience, and regulatory support services as part of the agreement [1] Group 2: Financial Aspects - The company will receive a significant upfront payment and milestone payments as part of the agreement [1] - Future royalties will be collected from the commercialization of the licensed technology, reflecting the mutual expectation of creating long-term value through this collaboration [1]

Core Viewpoint - The company has entered into a strategic partnership and non-exclusive technology licensing agreement with EirGenix, a global biopharmaceutical development and manufacturing enterprise, to utilize its HiCB platform for enhanced biopharmaceutical production efficiency [1][2] Group 1: Partnership and Agreement Details - The agreement grants EirGenix a non-exclusive license to the HiCB platform, which includes high-yield continuous perfusion upstream processes and integrated mixed continuous downstream purification technology [1] - The company will receive a significant upfront payment and milestone payments, along with future royalties from the commercialization of the licensed technology [1] Group 2: Technology and Benefits - The HiCB platform aims to achieve higher process efficiency, optimize process control, and ensure product consistency, significantly reducing production costs compared to traditional fed-batch production methods [1] - This collaboration is expected to enhance the affordability and accessibility of high-quality biopharmaceuticals for patients globally [2] Group 3: Future Implications - The revenue generated from this and future collaborations will be reinvested into strengthening the technology platform and advancing the research and development pipeline for next-generation innovative therapies [2]

Core Insights - Transcenta Holding Limited has entered into a strategic collaboration and non-exclusive licensing agreement with EirGenix Inc to enhance biopharmaceutical manufacturing capabilities [1][2] Group 1: Collaboration Details - Transcenta will grant EirGenix a non-exclusive license to utilize its Highly Intensified Continuous Bioprocessing (HiCB) platform, which includes advanced continuous perfusion and hybrid continuous purification technologies [2][3] - The agreement includes substantial upfront and milestone payments, as well as future royalty payments based on the commercial use of the licensed technologies, indicating expected long-term value creation for both companies [2] Group 2: Technology and Benefits - The HiCB platform aims to improve process efficiency, control, and product consistency while significantly reducing the cost of goods compared to traditional fed-batch manufacturing processes, thereby enhancing global patient access to affordable biologics [3] - EirGenix plans to implement the HiCB platform to support its biologics development programs and manufacturing operations, particularly for clients seeking intensified and continuous manufacturing solutions [4] Group 3: Leadership Perspectives - Transcenta's leadership emphasizes the importance of the HiCB platform in transforming biologics manufacturing and aims to reinvest proceeds from collaborations to strengthen its technology and R&D pipeline [5] - EirGenix's leadership highlights the partnership as a win-win situation that combines Transcenta's innovation with EirGenix's expertise, aiming for more efficient and sustainable biologics production [5] Group 4: Company Background - Transcenta is a global clinical stage biopharmaceutical company with integrated capabilities in antibody-based biotherapeutics, with facilities in Suzhou and Hangzhou, and clinical development centers in China, the U.S., and Europe [6][7] - EirGenix is Taiwan's largest biologics CDMO, providing comprehensive services from cell line and process development to GMP manufacturing, and is also advancing its own biosimilar and ADC pipeline [8]

Core Insights - The company has entered into a strategic partnership and non-exclusive technology licensing agreement with EirGenix, a global biopharmaceutical development and manufacturing enterprise [1] - The agreement allows EirGenix to utilize the company's HiCB platform, which focuses on high-yield continuous flow upstream processes and integrated downstream purification technologies [1] - The partnership is expected to generate significant upfront and milestone payments, along with future royalties from the commercialization of the licensed technology [1] Group 1 - The HiCB platform aims to enhance process efficiency, optimize process control, and ensure product consistency, significantly reducing production costs compared to traditional fed-batch production methods [1] - EirGenix plans to leverage the HiCB platform to support its biopharmaceutical development projects and production operations, targeting CDMO clients seeking integrated continuous flow production solutions [1] Group 2 - The company's chairman and CEO, Dr. Qian Xueming, expressed enthusiasm about sharing the HiCB platform with like-minded partners to drive transformation in biopharmaceutical production [2] - The revenues generated from this and future collaborations will be reinvested into strengthening the technology platform and advancing the R&D pipeline for next-generation innovative therapies [2]

Transcenta Holding Limited 創勝集團醫藥有限公司 （以存續方式於開曼群島註冊的有限公司） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 （股份代號：6628） 自願公告 創勝集團宣佈達成一項戰略合作與非獨佔技術許可協議， 推進生物藥的一體化連續流生產，提升可負擔生物藥的全球可及性 本公告由創勝集團醫藥有限公司（「本公司」）自願作出，旨在告知本公司股東及潛 在投資者有關最新業務進展。本公告所用但並無另行界定的詞彙應與本公司日期 為2021年9月14日的招股章程中所賦予該等詞彙的涵義相同。 本公司董事會（「董事會」）欣然宣佈，已與全球生物製藥開發與生產企業，台康生 技股份有限公司（「EirGenix」）(TWSE: 6589)達成戰略合作與非獨佔技術許可協 議。 根據協議，公司將向EirGenix授予高度一體化連續流生物工藝製造(HiCB)平台的 非獨佔許可，涵蓋高產的連續灌流上游工藝與集成的混合連續下游純化技術，並 提供完整 ...

热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 香港联交所最新数据显示，12月18日，董事会主席钱雪明增持创胜集团（06628）1万股，每股作价 2.1435港元，总金额约为2.14万港元。增持后最新持股数目为3803万股，持股比例为8.4%。 责任编辑：卢昱君 香港联交所最新数据显示，12月18日，董事会主席钱雪明增持创胜集团（06628）1万股，每股作价 2.1435港元，总金额约为2.14万港元。增持后最新持股数目为3803万股，持股比例为8.4%。 责任编辑：卢昱君 ...

香港联交所最新数据显示，12月18日，董事会主席钱雪明增持创胜集团(06628)1万股，每股作价2.1435 港元，总金额约为2.14万港元。增持后最新持股数目为3803万股，持股比例为8.4%。 ...